N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine is a pharmaceutical intermediate for the synthesis of Osimertinib (AZD9291) used to treat non-small-cell lung carcinomas with a specific mutation.
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.
 M.R.Finlay, et al, J. Med. Chem., 2014, 57(20), pp 8249-8267.
 H.Zhang, et al, Eur. J. Med. Chem., 2017, 135, pp 12-23.